Precision phenotyping of elevated arousal in posttraumatic stress disorder: implications for personalized GABAergic pharmacotherapy (opens in new tab)

Posttraumatic stress disorder (PTSD) is a common and disabling condition, and current first-line medications have remission rates as low as 20-30%. Novel agents targeting the GABAergic system offer a promising alternative approach to treatment given converging evidence for a central role for this system in PTSD pathophysiology. However, overall progress in PTSD psychopharmacology has been hampered by the substantial heterogeneity in this population, which has been highlighted by recent resear...